This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brevetti, G. Articles by Marcialis, A. Search for Related Content PubMed PubMed Citation Articles by Brevetti, G. Articles by Marcialis, A.

Circulation, Vol 84, 1490-1495, Copyright © 1991 by American Heart Association

ARTICLES

Muscle carnitine deficiency in patients with severe peripheral vascular disease

G Brevetti, C Angelini, M Rosa, R Carrozzo, S Perna, M Corsi, A Matarazzo and A Marcialis
Department of Medicine, University of Naples Federico II, Italy.

BACKGROUND. This study was designed to evaluate the effect of severe peripheral arterial insufficiency on carnitine concentrations and carnitine acetyltransferase and palmitoyltransferase activities in the ischemic skeletal muscles of patients with severe peripheral vascular disease. METHODS AND RESULTS. Nine biopsy specimens of ischemic muscles were obtained from five patients undergoing reconstructive vascular surgery. Biopsies from 35 normal subjects served as controls. Ischemic muscles showed a significant reduction in total carnitine from the control value of 20.9 +/- 5.2 to 11.6 +/- 6.2 nmol/mg noncollagen protein (p less than 0.01). A significantly lower free carnitine and acylcarnitine content contributed to this reduction. Similarly, carnitine acetyltransferase activity was reduced in the ischemic muscles from the control value of 102.1 +/- 41.2 to 52.9 +/- 22.1 nmol/min/mg noncollagen protein (p less than 0.01). On the contrary, carnitine palmitoyltransferase activity did not show any change (0.29 +/- 0.05 nmol/min/mg noncollagen protein in the ischemic muscles and 0.28 +/- 0.07 nmol/min/mg noncollagen protein in controls). Carnitine, acylcarnitines, and enzyme activities were also measured in the ischemic muscles in four additional patients 2 days after intravenous administration of L-propionylcarnitine (1.5 g as a single bolus followed by an infusion of 1 mg/kg/min for 30 minutes). Treatment restored normal levels of carnitine and its esters in the ischemic muscles but did not affect enzyme activities. CONCLUSIONS. Demonstration of carnitine deficiency in severe peripheral vascular disease substantiates previous findings showing the efficacy of carnitine supplementation to ischemic muscles. Furthermore, the feasibility of restoring carnitine homeostasis with L- propionylcarnitine provides the basis for clinical trials aimed at assessing the efficacy of this carnitine ester in the treatment of peripheral vascular disease.

This article has been cited by other articles:

				G. M. Andreozzi, A. Leone, R. Laudani, R. Martin, G. Deinit, and V. Cataldi Levo-Propionyl-Carnitine Improves the Effectiveness of Supervised Physical Training on the Absolute Claudication Distance in Patients With Intermittent Claudication Angiology, March 1, 2008; 59(1): 84 - 89. [Abstract] [PDF]

				M. Malaguarnera, L. Cammalleri, M. P. Gargante, M. Vacante, V. Colonna, and M. Motta L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial Am. J. Clinical Nutrition, December 1, 2007; 86(6): 1738 - 1744. [Abstract] [Full Text] [PDF]

				A. Silvestro, V. Schiano, R. Bucur, G. Brevetti, F. Scopacasa, and M. Chiariello Effect of Propionylcarnitine on Changes in Endothelial Function and Plasma Levels of Adhesion Molecules Induced by Acute Exercise in Patients with Intermittent Claudication Angiology, March 1, 2006; 57(2): 145 - 154. [Abstract] [PDF]

				A. G. Cordente, E. Lopez-Vinas, M. I. Vazquez, J. H. Swiegers, I. S. Pretorius, P. Gomez-Puertas, F. G. Hegardt, G. Asins, and D. Serra Redesign of Carnitine Acetyltransferase Specificity by Protein Engineering J. Biol. Chem., August 6, 2004; 279(32): 33899 - 33908. [Abstract] [Full Text] [PDF]

				M. Condorelli and G. Brevetti Intermittent claudication: an historical perspective Eur. Heart J. Suppl., March 1, 2002; 4(suppl_B): B2 - B7. [Abstract] [PDF]

				J. Liu, D. W. Killilea, and B. N. Ames Age-associated mitochondrial oxidative decay: Improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L- carnitine and/or R-alpha -lipoic acid PNAS, February 19, 2002; 99(4): 1876 - 1881. [Abstract] [Full Text] [PDF]

				G. Brevetti, C. Diehm, D. Lambert, and on behalf of the Study Investigators European multicenter study on propionyl-L-carnitine in intermittent claudication J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1618 - 1624. [Abstract] [Full Text] [PDF]

				G. Brevetti, F. di Lisa, S. Perna, R. Menabo, R. Barbato, V. Domenico Martone, and N. Siliprandi Carnitine-Related Alterations in Patients With Intermittent Claudication : Indication for a Focused Carnitine Therapy Circulation, May 1, 1996; 93(9): 1685 - 1689. [Abstract] [Full Text]